Rhenman & Partners Asset Management Ab Tg Therapeutics, Inc. Transaction History
Rhenman & Partners Asset Management Ab
- $840 Million
- Q1 2025
A detailed history of Rhenman & Partners Asset Management Ab transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Rhenman & Partners Asset Management Ab holds 177,500 shares of TGTX stock, worth $6.32 Million. This represents 0.83% of its overall portfolio holdings.
Number of Shares
177,500
Previous 262,500
32.38%
Holding current value
$6.32 Million
Previous $7.9 Million
11.43%
% of portfolio
0.83%
Previous 0.82%
Shares
8 transactions
Others Institutions Holding TGTX
# of Institutions
416Shares Held
88.1MCall Options Held
2.34MPut Options Held
1.94M-
Vanguard Group Inc Valley Forge, PA15.6MShares$556 Million0.01% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$406 Million0.0% of portfolio
-
State Street Corp Boston, MA7.43MShares$265 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA3.28MShares$117 Million0.01% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT2.85MShares$101 Million9.29% of portfolio
About TG THERAPEUTICS, INC.
- Ticker TGTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 145,274,000
- Market Cap $5.18B
- Description
- TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...